News &
Publications

Contacts

Franklin Hoke
Vice President
for Communications
215-728-2700
215-475-2888 (cell phone)
Franklin.Hoke@fccc.edu

Diana Quattrone
Director of Media Relations
215-728-7784
215-815-7828 (cell phone)
Diana.Quattrone@fccc.edu

Communications Staff

 

News

Foundations and Corporations Give Generously to Fox Chase Cancer Center's Prevention Campaign

PHILADELPHIA (December 4,1998) -- Fox Chase Cancer Center's $38 million campaign to launch the nation's first comprehensive Research Institute for Cancer Prevention has already attained more than 75 percent of its goal. Nonprofit foundations around the country as well as companies based locally and abroad have been magnanimous in their support.

"Our board of directors set the pace with generous early gifts, and many foundation and corporate donors have continued their longtime support of Fox Chase programs with major contributions to this campaign," said Center president Dr. Robert C. Young. "Fox Chase is grateful for these commitments as well as for those of first-time donors."

Early leadership gifts included $12.5 million from six foundations: The Connelly Foundation of West Conshohocken, Pa., The Dyson Foundation of Millerton, N.Y., the Hamilton Family Foundation of Wayne, Pa., The Kresge Foundation of Troy, Mich., The Pew Charitable Trusts of Philadelphia and The W. W. Smith Charitable Trust of Newtown Square, Pa.

A total of $4.8 million has come from 10 corporate donors:

  • Berlex Laboratories, based in New Jersey and Richmond, Calif.;
  • BetzDearborn Inc. of Trevose, Pa., a newly acquired chemical subsidiary of Hercules Inc. of Wilmington, Del.;
  • Bristol-Myers Squibb Company, whose oncology division is based in Princeton, N.J.;
  • Crown Cork & Seal Co. of Philadelphia;
  • Novartis Pharmaceuticals Corporation, located in East Hanover, N.J.
  • Ortho Biotech Inc. and Janssen Pharmaceutica, New Jersey-based members of the Johnson & Johnson family of companies;
  • Rhne-Poulenc Rorer, a Collegeville, Pa.-based subsidiary of Rhne-Poulenc S.A. of Paris, France;
  • Rohm and Haas Company of Philadelphia;
  • and SmithKline Beecham of Philadelphia and London, England.

"Gifts like these represent a tremendous vote of confidence in the prevention concept and its timeliness for today," Young said.

Much of this support will help fund construction of the Prevention Pavilion that will house the new Fox Chase research initiative. The building represents $20 million of the $38 million campaign target while the remaining $18 million will be allocated to endowed faculty chairs and postdoctoral fellowships, new research programs and laboratory equipment.

The Kresge Foundation's 1998 challenge grant of $1.5 million requires Fox Chase to raise more than $5.4 million in new gifts and grants by September 1999 to complete funding of the new building before the Foundation releases its funds. The grant is one of the largest challenge grants Kresge has made this year and the largest ever made to a Pennsylvania institution. To date, Fox Chase has raised more than $3.7 million to meet the Kresge challenge.

The five-level, 120,000-square-foot Prevention Pavilion is expected to be finished in January 2000. Groundbreaking took place May 14.

Scientific investigations to be pursued in the Research Institute for Cancer Prevention include programs in genetics; genetic epidemiology--the study of disease patterns on a molecular level; risk assessment; behavioral medicine; chemoprevention--the use of medication to prevent cancer; and bioinformatics. In addition to research laboratories, the Prevention Pavilion will house clinical programs for people at high risk of cancer, including genetically driven cancer screening and counseling.

Fox Chase Cancer Center is one of 35 National Cancer Institute-designated comprehensive cancer centers in the nation. The Center's activities include basic and clinical research; prevention, detection and treatment of cancer; and community outreach programs.


Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

More 1998 News Releases »